MedTrace Logo

Study to Validate the Questionnaire Called IDSIQ™ in Patients With Insomnia Disorder

NCT03056053 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 113

Last updated 2019-07-24

No results posted yet for this study

Summary

The main study objective is to assess the content validity and the psychometric characteristics of the Insomnia Daytime Symptoms and Impacts Questionnaire™ (IDSIQ™).

Conditions

  • Insomnia Disorder

Interventions

DRUG

Zolpidem

Commercially available tablets of zolpidem (5 or 10 mg) for oral use

Sponsors & Collaborators

  • Idorsia Pharmaceuticals Ltd.

    lead INDUSTRY

Principal Investigators

  • Sara Mangialaio, MD · Actelion

Study Design

Allocation
NA
Purpose
OTHER
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-02-15
Primary Completion
2017-04-21
Completion
2017-05-05

Countries

  • United States
  • Germany

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03056053 on ClinicalTrials.gov